Adagene (ADAG) Preferred Stock Liabilities (2019 - 2025)
Adagene's (ADAG) quarterly Preferred Stock Liabilities came in at $16550.0 billion in Q4 2025, up 33099900.0% on a QoQ basis from $50.0 million in Q2 2021.
Adagene (ADAG) Preferred Stock Liabilities (2019 - 2025) Analysis & Trends
Adagene (ADAG) has 4 years of Preferred Stock Liabilities data on file, last reported at $16550.0 billion in Q4 2025.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $16550.0 billion in Q4 2025; TTM through Dec 2025 was $16550.0 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $16550.0 billion, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2025 stood at $16550.0 billion, up from $50.0 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for ADAG reached as high as $16550.0 billion in Q4 2025 and fell as low as $50.0 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Adagene | 198.85 Mn | 198.85 Mn | - | 16,550.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16,550.00 Bn |
| Jun 30, 2021 | 50.00 Mn |
| Dec 31, 2020 | 154.45 Mn |
| Dec 31, 2019 | 154.20 Mn |